AOL Money & Finance

Teva tries again with oral MS drug

Posted Nov 7th 2007 2:35PM by Aaron KatsmanAaron Katsman RSS Feed
Filed under: Teva Pharm Indus ADR (TEVA), Israel

More

Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA), the largest generic drug maker in the world, has begun enrolling patients in the Phase III clinical trial of oral laquinimod for the treatment of relapsing-remitting multiple sclerosis. The plan is to have 1,000 patients in the trial, which will last between 2-3 years.

Teva already produces Copaxone for the treatment of MS, but has twice tried unsuccessfully in the past to produce an oral drug. This time it is teaming up with the Swedish drug company Active Biotech to trial the oral drug.

If successful, along with Copaxone, Teva will be the clear leader in the fight to treat MS. For the sake of all who suffer from MS, let's hope the third time is a charm, and Teva has success with the oral drug.

Aaron Katsman is the lead Portfolio Manager and Managing Director of America Israel Investment Associates, LLC. and Senior Editor of IsraelNewsletter.com. Author holds a position in TEVA.

Tags: copaxone, generic drugs, GenericDrugs, inthenews, ms, teva

Symbol Lookup
IndexesChangePrice
DJIA+30.6910,464.40
NASDAQ+6.872,176.05
S&P 500+4.981,110.63

Last updated: November 25, 2009: 04:18 PM

BloggingStocks Exclusives

Hot Stocks

DailyFinance Headlines

Latest from BloggingBuyouts

TheFlyOnTheWall.com Headlines

BioHealth Investor Headlines

WalletPop Headlines

My Portfolios

Track your stocks here!

Find out why more people track their portfolios on AOL Money & Finance then anywhere else.

  • My Portfolio
  • Create a New Portfolio

BloggingStocks Partners

More from AOL Money & Finance

WalletPop Headlines